PRMT3 and glioblastoma: The WST-1 assay showed that treatment of GBM cells (U251, U87) and patient-derived GSC cells (GSC28 and GSC262) with the PRMT3 selective inhibitor SGC707 significantly reduced cell growth (Fig. 8A, B), while it did not affect the cell growth of normal brain glial cell lines, HEB and HMO6, at the same concentration (Fig. 8C).